- Home
- INMB vs ZYXI Comparison
INMB vs ZYXI Comparison
Compare INMB & ZYXI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INMB
- ZYXI
- Stock Information
- Founded
- INMB 2015
- ZYXI 1996
- Country
- INMB United States
- ZYXI United States
- Employees
- INMB N/A
- ZYXI N/A
- Industry
- INMB Biotechnology: Pharmaceutical Preparations
- ZYXI Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- INMB Health Care
- ZYXI Health Care
- Exchange
- INMB Nasdaq
- ZYXI Nasdaq
- Market Cap
- INMB 49.2M
- ZYXI 44.8M
- IPO Year
- INMB 2019
- ZYXI N/A
- Fundamental
- Price
- INMB $1.87
- ZYXI $1.34
- Analyst Decision
- INMB Hold
- ZYXI Hold
- Analyst Count
- INMB 3
- ZYXI 3
- Target Price
- INMB $4.30
- ZYXI $3.00
- AVG Volume (30 Days)
- INMB 349.2K
- ZYXI 74.3K
- Earning Date
- INMB 10-30-2025
- ZYXI 10-30-2025
- Dividend Yield
- INMB N/A
- ZYXI N/A
- EPS Growth
- INMB N/A
- ZYXI N/A
- EPS
- INMB N/A
- ZYXI N/A
- Revenue
- INMB $50,000.00
- ZYXI $144,808,000.00
- Revenue This Year
- INMB $264.29
- ZYXI N/A
- Revenue Next Year
- INMB $9,819.61
- ZYXI $7.07
- P/E Ratio
- INMB N/A
- ZYXI N/A
- Revenue Growth
- INMB N/A
- ZYXI N/A
- 52 Week Low
- INMB $1.71
- ZYXI $1.23
- 52 Week High
- INMB $11.64
- ZYXI $9.33
- Technical
- Relative Strength Index (RSI)
- INMB 45.15
- ZYXI 41.38
- Support Level
- INMB $1.79
- ZYXI $1.30
- Resistance Level
- INMB $1.95
- ZYXI $1.43
- Average True Range (ATR)
- INMB 0.10
- ZYXI 0.07
- MACD
- INMB 0.01
- ZYXI 0.00
- Stochastic Oscillator
- INMB 46.00
- ZYXI 20.59
About INMB INmune Bio Inc. Common stock
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products include INKmune, INBO3, XPro1595, LIVNate, and others.
About ZYXI Zynex Inc.
Zynex Inc is engaged in the manufacturing and marketing of medical devices. It operates through one primary business segment, Electrotherapy and Pain Management Products. The business activities of the company are carried out through its subsidiaries. The company designs, manufactures, and markets medical devices that treat chronic and acute pain, as well as activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company operates business as one operating segment which includes two revenue types: Devices and Supplies. Its markets Zynex-manufactured products which include NexWave, NeuroMove, InWave E-Wave, and others.